Tuesday, July 1, 2025 7/1/2025

Environment, Epigenetics, Neurodevelopment & Health of Extremely Preterm Children

Award Number: UH3OD023348
ORGANIZATION: OFFICE OF THE DIRECTOR, NIH
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/21/2016
PERIOD OF PERFORMANCE END DATE: 08/31/2023

Group Awards By:

View Award Description

Environment, Epigenetics, Neurodevelopment & Health of Extremely Preterm Children - Project Summary/Abstract The goal of the ECHO Consortium is to identify exposures and mechanisms that link the environment in early life to childhood development and health outcomes. This proposal commits to the ECHO Consortium numerous resources from the Extremely Low Gestation Age Newborn (ELGAN) Study. Since its initiation in 2001, the broad goal of the ELGAN Study is to evaluate the relationship between perinatal inflammation and neurodevelopmental impairments among individuals born extremely premature (i.e., before 28 weeks of gestation). In the proposed project we will build on the success of the ELGAN Study by adding new information about: 1) environment exposures, 2) neurodevelopmental outcomes of study participants at 15 and 18 years of age, and 3) placental epigenetic variation, a mechanism that could link inflammation early in life to neurodevelopmental impairments. In the first two years of the project (the UG3 phase) investigators from the ELGAN team will participate in the design of studies that can be implemented across the ECHO Consortium and in efforts to harmonize data across cohorts comprising the consortium. In the second year of the proposal, we will begin to evaluate members of the ELGAN cohort, as they reach 15 years of age, using standardized neurodevelopmental assessments and brain magnetic resonance imaging (MRI). We also will complete preliminary studies of relationships between prenatal environmental exposures, early life inflammation, and neurodevelopmental impairments, using extant data from the ELGAN cohort. In addition, we will complete analysis of epigenetic markers in placenta specimens collected around the time of the births of ELGAN Study participants. These data will be utilized in the last 5 years of the proposed project (the UH3 phase). If pre-specified milestones are met, the project will transition into the UH3 phase. Standardized neurodevelopmental assessments and brain magnetic resonance imaging (MRI) will be completed as study participants reach 15 years. As participants reach 18 years of age neurodevelopmental assessments will again be completed. At the assessment at 18 years we will obtain blood for study of epigenetic markers of activation of innate immunity, which we can then relate to our extant data about systemic inflammation early in life. Specific aims in the UH3 phase of the project are examine relationships between biomarkers of early life inflammation (extant data on neonatal systemic inflammation and new data on placenta epigenetics) and neurodevelopmental impairments through age 18 years. The over-arching hypothesis to be addressed is that prenatal exposures can initiate early life inflammation, thus increasing the risk of neurodevelopmental impairments. Innovative aspects of this project include its longitudinal perspective, consideration of placenta epigenetics as a mechanism linking prenatal exposures to childhood outcomes, and evaluation of a wide range of neurodevelopmental outcome. This research has the potential to inform the development of therapies targeting epigenetic processes to prevent or ameliorate cognitive disability, thereby improving the quality of life for 16,000 individuals who survive extremely premature birth each year in the United States.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$2,198,525 )
2024	2022	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	000	7	4/2/2024	NON-COMPETING CONTINUATION	-$2,198,525
														Subtotal = -$2,198,525

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	000	7	9/20/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $4,627,071 )
2022	2022	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	001	7	9/7/2022	NON-COMPETING CONTINUATION	$4,627,071
2022	2021	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	000	6	6/15/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $4,627,071

Issue Date FY: 2021 ( Subtotal = $4,206,281 )
2021	2021	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	006	6	8/26/2021	NON-COMPETING CONTINUATION	$4,110,690
2021	2021	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Child Health and Human Development Extramural Research	007	6	8/27/2021	SUPPLEMENT FOR EXPANSION	$72,341
2021	2020	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	005	5	8/5/2021	NON-COMPETING CONTINUATION	$0
2021	2018	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	001	3	4/7/2021	EXTENSION WITH OR WITHOUT FUNDS	-$23,250
2021	2018	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	003	3	4/7/2021	EXTENSION WITH OR WITHOUT FUNDS	-$765,033
2021	2018	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	002	3	4/7/2021	EXTENSION WITH OR WITHOUT FUNDS	-$754
2021	2018	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	004	3	4/13/2021	EXTENSION WITH OR WITHOUT FUNDS	$789,037
2021	2018	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	000	3	3/29/2021	EXTENSION WITH OR WITHOUT FUNDS	$23,250
														Subtotal = $4,206,281

Issue Date FY: 2020 ( Subtotal = $4,492,503 )
2020	2020	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	003	5	8/19/2020	SUPPLEMENT FOR EXPANSION	$311,000
2020	2020	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	004	5	9/9/2020	SUPPLEMENT FOR EXPANSION	$0
2020	2020	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	002	5	8/18/2020	SUPPLEMENT FOR EXPANSION	$70,059
2020	2020	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	001	5	8/17/2020	NON-COMPETING CONTINUATION	$4,110,690
2020	2018	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	000	3	1/14/2020	EXTENSION WITH OR WITHOUT FUNDS	$754
														Subtotal = $4,492,503

Issue Date FY: 2019 ( Subtotal = $5,225,723 )
2019	2019	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	002	4	9/12/2019	NON-COMPETING CONTINUATION	$4,460,690
2019	2018	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	000	3	2/8/2019	EXTENSION WITH OR WITHOUT FUNDS	$765,033
2019	2018	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	001	3	6/24/2019	EXTENSION WITH OR WITHOUT FUNDS	$0
														Subtotal = $5,225,723

Issue Date FY: 2018 ( Subtotal = $4,119,664 )
2018	2018	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Trans-NIH Research Support	000	3	8/29/2018	EXTENSION WITH OR WITHOUT FUNDS	$4,119,664
														Subtotal = $4,119,664

Grand Total All Awards = $20,472,717

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Environment, Epigenetics, Neurodevelopment & Health of Extremely Preterm Children

Award Number: UH3OD023348

ORGANIZATION: OFFICE OF THE DIRECTOR, NIH

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/21/2016

PERIOD OF PERFORMANCE END DATE: 08/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer